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Abstract
Red blood cell (RBC) alloimmunization is a significant clinical complication of sickle cell disease 
(SCD). It can lead to difficulty with cross-matching for future transfusions and may sometimes 
trigger life-threatening delayed hemolytic transfusion reactions. We conducted a retrospective 
study to explore the association of clinical complications and age of RBC with alloimmunization 
in patients with SCD followed at a single institution from 2005 to 2012. One hundred and sixty six 
patients with a total of 488 RBC transfusions were evaluated. Nineteen patients (11%) developed 
new alloantibodies following blood transfusions during the period of review. The median age of 
RBC units was 20 days (interquartile range: 14–27 days). RBC antibody formation was 
significantly associated with the age of RBC units (P = 0.002), with a hazard ratio of 3.5 (95% CI: 
1.71–7.11) for a RBC unit that was 7 days old and 9.8 (95% CI: 2.66–35.97) for a unit that was 35 
days old, 28 days after the blood transfusion. No association was observed between RBC 
alloimmunization and acute vaso-occlusive complications. Although increased echocardiography-
derived tricuspid regurgitant jet velocity (TRV) was associated with the presence of RBC 
alloantibodies (P = 0.02), TRV was not significantly associated with alloimmunization when 
adjusted for patient age and number of transfused RBC units. Our study suggests that RBC 
*Correspondence to: Kenneth I. Ataga, MBBS, Division of Hematology/Oncology, University of North Carolina at Chapel Hill, 
Physicians’ Office Bldg., 3rd Floor, CB# 7305, 170 Manning Drive, Chapel Hill, NC 27599-7305. kataga@med.unc.edu. 
Conflict of Interest: The authors have no conflicts of interest to disclose.
Author Contributions
P.C. Desai designed research, interpreted data, and wrote the manuscript; A.M. Deal performed statistical analysis, interpreted data 
and wrote the manuscript; E. R. Pfaff collected data and critically reviewed the manuscript; B. Qaqish performed statistical analysis, 
interpreted the data and critically reviewed the manuscript; L.M. Hebden collected data and critically reviewed the manuscript; Y Park 
interpreted data and critically reviewed the manuscript; K.I. Ataga designed research, interpreted data, and wrote the manuscript.
HHS Public Access
Author manuscript
Am J Hematol. Author manuscript; available in PMC 2016 September 14.
Published in final edited form as:













antibody formation is significantly associated with older age of RBCs at the time of transfusion. 
Prospective studies in patients with SCD are required to confirm this finding.
Introduction
Red blood cell (RBC) transfusion therapy is an important management strategy in sickle cell 
disease (SCD) for several acute and chronic indications [1–5]. Data from the Cooperative 
Study of Sickle Cell Disease show that most patients over the age of 20-years have received 
a RBC transfusion [6]. Despite its benefits, RBC transfusion has multiple complications 
[3,5–8]. Alloimmunization, the development of a clinically significant antibody to a RBC 
antigen, is an important complication following RBC transfusion therapy. Alloimmunization 
leads to both acute and delayed hemolytic transfusion reactions and limits the availability of 
compatible blood for future transfusions. The rates of RBC alloimmunization in the US 
population are reported to range from 18 to 36% [6,9]. In the Jamaican population where 
blood is racially matched, the rate of alloimmunization is only 2.6% [8], whereas in the 
United Kingdom where most transfusions are racially mismatched, the rate of 
alloimmunization has been reported to be as high as 76% [8]. The increased frequency of 
RBC alloimmunization in SCD patients has been hypothesized to be due to incompatibility 
of minor RBC antigens due to a donor pool of racially mismatched blood [10]. More 
recently, it has been reported that specific Rh variants are more frequent in individuals of 
African descent, and SCD patients may develop alloantibodies despite testing positive for 
these antigens on serologic studies [11]. Additional risk factors associated with 
alloimmunization include increased number of transfusions, older age of patient at the time 
of first transfusion, and female gender [12–14].
A murine model of alloimmunization to RBC antigens exposed to poly(I:C), a synthetic 
double-stranded RNA molecule that induces viral-like inflammation, demonstrated a 
significant enhancement of humoral immunization both in frequency and magnitude to 
transfused alloantigens [13,15]. This suggests that, in addition to having the “responder” 
phenotype, other host factors such as inflammation may contribute to the pathophysiology of 
alloimmunization. Patients with SCD exhibit marked elevation of inflammatory markers at 
baseline, which are further increased during acute vaso-occlusive episodes [16–21]. In 
addition, stored RBCs have been reported to produce higher rates of immunogenicity than 
fresh blood in a murine model for alloimmunization [22].
With the evidence that inflammation and RBC age play complex regulatory roles in RBC 
alloimmunization in murine models, we conducted a retrospective study to evaluate the 
association of clinical complications and age of RBCs with alloimmunization in patients 
with SCD.
Methods
We conducted a retrospective chart review to explore the association of clinical 
complications and age of RBC with alloimmunization in patients with SCD followed at the 
University of North Carolina at Chapel Hill from 2005 to 2012. As is the standard of care at 
our center, all patients were transfused with RBC units that were at a minimum, matched for 
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Rh C, c, D, E and Kell antigens. A list of patients was generated using the following ICD-9 
codes for SCD: 282. 60 Sickle cell anemia NOS, 282.61 HbSS without Crisis, 282.62 HbSS 
with Crisis, 282.63 Sickle cell/HbC disease without crisis, 282.64 Sickle cell/HbC disease 
with crisis, 282.41 Sickle Cell Thalassemia without crisis, 282.42 Sickle Cell Thalassemia 
with crisis, 282.68 Other sickle-cell disease without crisis, 282.69 Other SCD with crisis, 
289.52 Splenic sequestration, and 517.3 Acute chest syndrome. This query was combined 
with blood bank query for the following codes: Transfuse Packed Red Cells, Packed Red 
Cells, Transfuse Packed Cell – PRBC’s. The data mining was supplemented by a physical 
review of medical history and blood bank records.
Patients were included in the study if they had a confirmed diagnosis of SCD and a type and 
screen following RBC transfusion. If a patient was transfused with RBCs, a new type and 
screen was usually obtained prior to the next transfusion beyond 72 hours. Patients were 
excluded if they were on chronic exchange transfusion, did not have a type and screen 
following transfusion or had a history of bone marrow transplantation. Transfusions were 
categorized into 2 groups: transfusions for acute vaso-occlusive complications (acute chest 
syndrome and vaso-occlusive crisis) versus other indications for transfusion (subsequently 
referred to as non-acute indications). All clinical complications (acute pain crises, active 
infection, acute chest syndrome, stroke, retinal artery occlusion, surgery, or leg ulcer) and 
use of hydroxyurea at the time of transfusion were noted. Follow up type and screens were 
evaluated for the formation of new antibodies.
Statistical Methods
Descriptive statistics are provided for all study variables, and comparisons between groups 
were made using Fisher’s exact tests for categorical variables and Wilcoxon rank sum tests 
for continuous variables. If multiple RBC units were transfused in a single transfusion, the 
average age of the RBC units was used. A multivariable logistic regression model was used 
to evaluate the combined effect of patient characteristics on the development of antibodies, 
using all data available from the last type and screen for each patient. Cox proportional 
hazard models were used to account for the time dependent nature of the data in describing 
the relationship with development of new antibodies. At each of the failure times (the time 
from baseline until the next type and screen detected a new antibody), we used data from all 
transfusions that occurred in the 60 day window prior to the failure time. We chose a 60 day 
window since a transfusion will not contribute to risk indefinitely and we assumed that the 
risk will be minimal after 2 months. All times were calculated from baseline, defined as the 
first type and screen, for each patient in the study period. A log transformation was used for 
the age of the RBCs to account for the skewed distribution. An additional sensitivity analysis 
was conducted, excluding patients who had received frozen RBC units. Variables were 
considered significantly associated with development of antibodies if the likelihood ratio p-
value for the model was significant at the 0.05 level. All analyses were conducted using SAS 
statistical software v9.3 (Cary, NC).
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One hundred and sixty six patients (HbSS = 121; HbSC = 25; HbSβ0 = 6; HbSβ+ = 9; other 
genotypes = 5), 94 of them females (57%) were evaluated during the study period. The mean 
patient age at the time of first transfusion during the period of study was 26 years (range: 5 
months – 72.4 years). The baseline demographics of the study patients at the start of the 
follow-up period are shown in Table I. There were a total of 488 transfusions and 652 types 
and screens in the study patients between September 2005 and July 2012. Most patients 
(82%) had received at least one RBC transfusion prior to the study period. The median time 
in the study (defined as time from first to last type and screen) was 1.04 years (interquartile 
range [IQR]: 69 days – 2.82 years). The median number of transfusions was 2 (IQR: 1–4) 
and the median number of types and screens was 3 (IQR: 2–4). The median number of RBC 
units per transfusion was 2 (IQR: 1 – 3), and the median age of transfused RBCs was 20 
days (IQR: 14–27). Nine patients were transfused with frozen RBC units, for a total of 16 
transfusions (age of RBC units [range]: 78 – 3640 days). Patients received only one unit of 
RBC in 260 of the 495 transfusion events (53%). For those patients who received more than 
one unit of RBC, we averaged the age of the RBC units for our analysis. The difference in 
the age of RBC was less than 10 days in 74% of transfusion events involving more than 1 
unit of RBC. Follow-up types and screens were obtained for all patients with a median time 
of 42 days (IQR: 9–198 days). Fifty seven percent of the follow-up types and screens were 
obtained within 60 days of the RBC transfusion.
Transfusions occurred for varied reasons, including symptomatic anemia associated with 
acute painful episodes (59%), acute chest syndrome (33%), acute stroke (1.6%), leg ulcers 
(10%), acute retinal artery occlusion (1%) and surgery (26%). In 19% of transfusions, 
patients had laboratory confirmed infections. Patients were taking hydroxyurea on the day of 
transfusion in 27% of transfusions. Patients were transfused for acute vaso-occlusive 
complications (acute painful episodes or acute chest syndrome) in 61% of cases. Overall, 
40% of patients received transfusions for only acute vaso-occlusive indications, 34% 
received only non-acute transfusions, and 26% received transfusions for nonacute as well as 
for acute vaso-occlusive indications.
Twenty-seven patients (16%) were known to have RBC antibodies at the start of the study 
period. Four of these patients (15%) had an additional antibody detected during a subsequent 
type and screen (median of 33.5 days after first transfusion during the study period). Of the 
139 (84%) patients who did not have any antibodies at the start of the study period, 15 
(10.6%) had an antibody identified during a subsequent type and screen. Overall, 19 patients 
(11%) developed a total of 25 new alloantibodies during the study period. Two of the 19 
patients who developed new alloantibodies did so following multiple RBC transfusions 
within the 72-hr type and screen window. One patient with a new antibody was excluded 
from the analysis as she was transfused at an outside facility and the details of the 
transfusion were unknown. Following the last type and screen during the study period, 42 
patients (25%) had at least one antibody detected (15 new patients, in addition to the 27 who 
had at least one antibody at the start of the study). The alloantibodies detected included 
Anti-C,-Cob, -Cw, -E, -Fya -Jka, -Jkb, -Jsa, -K, -Lea, -M, -S, and -V. Of the identified 
antibodies, 11 were targeted against Rh antigens.
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Associations with ever having an antibody detected were evaluated based on patient 
characteristics at the last type and screen during the study period (Table II). Patients with 
tricuspid regurgitant jet velocities (TRV) ≥2.5 m/s were significantly more likely to have 
antibodies than patients with TRV < 2.5 m/s (50% vs. 22%, P = 0.02). There were no 
associations between genotype, gender, use of hydroxyurea, or other evaluated clinical 
complications and RBC antibody formation (P > 0.05). There was no difference in antibody 
formation when patients who had been transfused for acute vaso-occlusive indications 
during the study period were compared with patients only transfused for nonacute 
indications (P = 0.9). Patients who developed antibodies were older (median age: 31 years 
[IQR: 22–49] vs. 22 years [IQR: 12–39], P = 0.0006) and had received more RBC 
transfusions (median number of transfusions: 2.5 [IQR: 1–4] vs. 2 [IQR: 1–3], P = 0.023) 
than patients who did not develop antibodies. A multivariable model including TRV, age, 
and number of transfusions revealed that TRV was no longer associated with the 
development of antibodies after controlling for patient age and the number of transfusions (P 
= 0.5). However, both increasing age and the number of RBC transfusions retained their 
significant associations with higher risk of developing antibodies (P = 0.01 and 0.04, 
respectively).
As relatively few patients developed new antibodies, Cox proportional hazards models were 
fit using one to two variables at a time. Time since transfusion was considered, in addition to 
mean age of the blood, number of RBC units, and transfusion for acute vaso-occlusive 
indications in three separate models. Neither the number of units (P = 0.16) nor having any 
transfusions for acute vaso-occlusive indications (P = 0.64) was significantly associated with 
the development of new antibodies. However, there was a significant association between the 
mean age of RBCs and the development of antibody (P = 0.002; Fig. 1). The estimated 
hazard ratio for a 7 day old RBC unit is 1.5 (95% CI: 1.15 – 2.02) on day 7 and 3.5 (95% CI: 
1.71 – 7.11) on day 28, while the estimated hazard ratio for a 35 day old RBC unit is 2.2 
(95% CI: 1.29 – 3.60) on day 7 and 9.8 (95% CI: 2.66 – 35.97) on day 28 (Table III). This 
means, for example, that if a patient was transfused on day one with 7-day-old RBC units, 
his/her hazard of developing antibodies at day 28 was 3.5 times that of a person who did not 
receive a transfusion on day one.
As frozen RBC units are processed and may age differently compared with nonfrozen RBC 
units, we ran similar analyses using only patients who were not transfused with any frozen 
RBC units; 9 patients who ever received frozen units were excluded. The association 
between the mean age of RBCs and the development of antibody remained, with similar 
estimated hazard ratios (Table III), but was no longer statistically significant (P = 0.053), 
likely due to the smaller number of events.
Discussion
In this study, we observed the relationship between the age of RBCs and alloimmunization. 
RBCs stored for up to 42 days prior to transfusion meet licensure requirements of allowing 
75% of the cells to remain in the circulation 24 hr after infusion [23]. However, older RBCs 
approaching the 42 day expiration mark have numerous attributes that may increase 
inflammation in the recipient and develop what is described as a storage lesion [24–28]. 
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Older RBCs have higher intracellular heme, which may overwhelm the heme oxygenase 
system that normally neutralizes the oxidative and inflammatory effects of heme [24]; 
increased plasma non-transferrin-bound iron, which may lead to increased risk of sepsis and 
possibly mortality [25]; higher RBC membrane loss, which may result in phospholipid 
changes, and the release of microparticles (which are considered procoagulant and 
proinflammatory) [26]; and lower levels of nitric oxide, due in large part to ongoing 
hemolysis and generation of reactive oxygen species [27,28]. Increased RBC age is 
associated with increased mortality, as well as higher risk of renal failure, pneumonia, deep 
venous thrombosis, and postoperative infections in critically ill patients, cardiovascular 
surgery patients, and in patients with trauma [29–31]. Considering the important role of 
RBC transfusion in the prevention and treatment of many SCD-related complications, our 
observation of an association between RBC age and alloimmunization may have important 
implications for clinical practice.
We did not observe any association between transfusion for acute complications, such as 
ongoing painful episodes or acute chest syndrome, and new RBC antibody formation. 
Although it has been reported that the baseline increased inflammatory state in SCD 
increases even further during acute painful episodes and acute chest syndrome [32–35], no 
inflammatory markers were measured in our retrospective study. As such, prospective 
studies in which inflammatory markers are assessed are required to definitively exclude a 
role for inflammation in alloimmunization in SCD. The increased alloimmunization in 
patients with increased TRV on univariate analysis was unexpected. However, TRV was not 
significantly associated with alloimmunization when adjusted for patient age and the number 
of RBC transfusions.
The study has limitations due to its retrospective design and small number of patients with 
new antibody formation. Follow up types and screens were obtained in patients on average 
42 days after a RBC transfusion, with occasional delays greater than sixty days in obtaining 
a type and screen following a RBC transfusion. As such, we may not have captured all 
formed alloantibodies. In addition, a type and screen was not always performed immediately 
before each transfusion, usually due to multiple transfusions within a 72 hr period. In such 
cases, we cannot directly attribute the development of antibodies to a particular transfusion. 
As a result, a repeated measures analysis at the transfusion level could not be performed. 
However, the rate of alloimmunization in our study is comparable to those obtained in 
studies that have examined antibody formation in SCD patients transfused with RBC units 
matched for Rh C, D, E, and Kell antigens [29]. Patients on chronic RBC exchange 
transfusion were excluded due to the anticipated difficulty in ascertaining the contribution of 
RBC age to antibody formation in patients on such treatment. In situations where patients 
were transfused with multiple RBC units in close proximity, we cannot directly attribute the 
development of antibodies to a particular transfusion. However, our analysis takes this into 
account by using the information from all transfusions within 60 days prior to each event 
time in the Cox proportional hazards model. Finally, as frozen RBC units are processed and 
age differently from nonfrozen RBC units, we conducted a sensitivity analysis excluding 
patients transfused with frozen RBC units. The results were similar, although not statistically 
significant, likely due to the smaller number of events when frozen units were excluded. As 
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only four patients transfused with frozen RBC units developed new antibodies, we did not 
evaluate the association of these units with alloimmunization.
In summary, transfusion for acute vaso-occlusive complications was not associated with 
increased alloimmunization in our retrospective study. However, RBC antibody formation 
was significantly associated with increased patient age and the number of transfused RBC 
units. In addition, following adjustment for the number of RBC units and transfusion for 
acute vaso-occlusive indications, older age of RBCs at the time of transfusion was 
significantly associated with RBC antibody formation. This finding is consistent with the 
reports indicating that older age of RBCs leads to higher levels of oxidative stress, and 
possibly subsequent increase in morbidity and mortality. Our findings warrant further 
investigation in a prospective study evaluating the role of RBC age in alloimmunization in 
patients with SCD.
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The model evaluating mean age of red blood cells shows that the hazard of developing new 
antibodies increases and then decreases over the 60 days following the transfusion, with a 
peak at 47 days. Each separate line shows the hazard of developing antibodies for a 
transfusion compared to a patient not transfused, for different ages of blood.
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TABLE I
Baseline Patient Demographics (n = 168)
Variable Frequency or median (IQRa)








African American 161 (97%)
Tricuspid regurgitant Jet Velocity≥2.5 (m/s) 15 (9%)
Avascular necrosis 38 (23%)
History of stroke 9 (5%)
Retinopathy 23 (14%)
Number of patients with prior antibodies 27 (16%)
Number of transfusions/patient 2 (1–4; range: 1–38 Transfusions)
Number of units/transfusion 2 (1–3; range: 1–15 Units)
Age of RBC units 20 days (14–27; range: 2–42 days)
a
IQR: interquartile range.
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TABLE II
Association Between Clinical Variables at End of Study and RBC Alloimmunizationa
Variable Frequency (%) P-value
Genotype SS 33/121 (27%) 0.6
SC 6/25 (24%)
Other 3/19 (16%)
Gender Male 16/72 (22%) 0.5
Female 26/94 (28%)
Indication for Transfusion Acute Vaso-occlusive Indication 26/100 (26%) 0.9
Nonacute Indication 16/66 (24%)
TRV≥2.5 (m/s) Yes 9/18 (50%) 0.02
No 33/148 (22%)
History of leg ulcers Yes 7/16 (43%) 0.1
No 35/150 (23%)
History of AVN Yes 14/39 (36%) 0.09
No 28/127 (22%)
History of ACS Yes 36/127 (28%) 0.1
No 6/39 (15%)
History of Stroke Yes 2/10 (20%) 0.9
No 40/156 (25%)
History of Retinopathy Yes 10/25 (40%) 0.08
No 32/141 (23%)
Use of Hydroxyurea Yes 20/60 (33.3%) 0.09
No 84/106 (79.2%)
a
Using summary data at the time of the last type and screen on study.
TRV: tricuspid regurgitant jet velocity.
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